Altimmune, Inc. announced a CEO succession plan with Vipin Garg, Ph.D. stepping down as President and CEO, effective January 1, 2026.
Jerry Durso, the Chairman of the Board, will assume the role of President and CEO.
Dr. Garg will serve as an advisor to the Company through June 30, 2026, ensuring a smooth transition.
CEO Transition
Vipin Garg, Ph.D., is stepping down as CEO, with Jerry Durso taking over the role.
Pipeline Advancements
Under Dr. Garg's leadership, Altimmune's lead pipeline candidate, pemvidutide, advanced to a Phase 3 ready program in metabolic dysfunction-associated steatohepatitis (MASH).
Pemvidutide Benefits
Pemvidutide, a dual glucagon and GLP-1 receptor agonist, shows significant weight loss and reductions in liver inflammation and fibrosis in patients with MASH.
- Jerry Durso brings over 30 years of leadership experience in the life sciences industry, with a focus on liver diseases and corporate strategy.
- Altimmune is preparing for a late-stage clinical phase and commercialization, highlighting the potential benefits of pemvidutide for patients with liver disease.
The transition in leadership at Altimmune marks a significant milestone as the company gears up for further growth and development under new leadership.